KOB 03

Drug Profile

KOB 03

Alternative Names: KOB-03

Latest Information Update: 16 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dongguk University
  • Developer Dong Wha Pharmaceutical; Dongguk University
  • Class Anti-inflammatories; Antiallergics; Herbal medicines
  • Mechanism of Action Cytokine inhibitors; Extracellular signal-regulated MAP kinase inhibitors; Gene expression inhibitors; Histamine release inhibitors; Immunomodulators; Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; Interleukin 8 inhibitors; Mast cell modulators; NF-kappa B inhibitors; P38 mitogen-activated protein kinase inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic rhinitis

Most Recent Events

  • 16 Dec 2015 Phase-II development for Allergic rhinitis is ongoing in South Korea
  • 15 Nov 2013 Dongguk University and Dong Wha Pharmaceuticals enter into technology transfer agreement for the development of KOB 03
  • 15 Nov 2013 Phase-II clinical trials in Allergic rhinitis in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top